GRANULOCYTE COLONY-STIMULATING FACTOR AMELIORATES LIFE-THREATENING INFECTIONS FOLLOWING COMBINED THERAPY OF BARBITURATES AND MILD HYPOTHERMIA IN SEVERE HEAD INJURY PATIENTS

1998 ◽  
Vol 45 (1) ◽  
pp. 191
Author(s):  
K. Ishikawa ◽  
H. Tanaka ◽  
M. Takaoka ◽  
H. Ogura ◽  
T. Shiozaki ◽  
...  
Keyword(s):  
Head Injury ◽  
Severe Head Injury ◽  
Mild Hypothermia ◽  
Combined Therapy ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Life Threatening ◽  
Stimulating Factor

Atraumatic idiopathic splenic rupture induced by granulocyte-colony stimulating factor (G-CSF) for the treatment of pancytopenia, managed successfully by laparoscopic splenectomy

2020 ◽  
Vol 13 (4) ◽  
pp. e232411 ◽  
Author(s):  
Ugochukwu Chinyere Chinaka ◽  
Joshua Fultang ◽  
Jelizaveta Pereca ◽  
Abdulmajid Ali
Keyword(s):  
Laparoscopic Splenectomy ◽  
Splenic Rupture ◽  
University Hospital ◽  
Haemodynamic Instability ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Threatening Condition ◽  
Life Threatening ◽  
Stimulating Factor ◽  
Factor G

Splenic rupture is a potentially life-threatening condition and an uncommon short-term complication of granulocyte-colony stimulating factor (G-CSF) administration. It may present as acute abdominal pain or suddenly precipitously worsening anaemia with haemodynamic instability that requires urgent operative intervention for survival. We present a case of an atraumatic idiopathic splenic rupture in University Hospital, Ayr in a patient who received G-CSF treatment for chemotherapy-induced (methotrexate) pancytopenia and was successfully managed by laparoscopic splenectomy.

Granulocyte-Colony Stimulating Factor (G-CSF) Ameliorates Negative Outcome after Mild Hypothermia (32°C) in Septic Rats

2002 ◽  
Vol 96 (Sup 2) ◽  
pp. A406
Author(s):  
Alexander Torossian ◽  
Sebastian Ruehlmann ◽  
Wilfried Lorenz ◽  
Hinnerk Wulf ◽  
Artur Bauhofer
Keyword(s):  
Mild Hypothermia ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Stimulating Factor ◽  
Factor G ◽  
Negative Outcome

scholarly journals Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation

Blood ◽  
2014 ◽  
Vol 123 (23) ◽  
pp. 3655-3663 ◽  
Author(s):  
Michael A. Pulsipher ◽  
Pintip Chitphakdithai ◽  
Brent R. Logan ◽  
Willis H. Navarro ◽  
John E. Levine ◽  
...  
Keyword(s):  
Adverse Events ◽  
Lower Risk ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Serious Adverse Events ◽  
Increased Risk ◽  
Key Points ◽  
Life Threatening ◽  
Stimulating Factor

Key Points BM donors have a threefold higher risk for life-threatening, serious unexpected, or chronic adverse events vs PBSC donors (0.99% vs 0.31%). Donors receiving granulocyte colony-stimulating factor for PBSC collection had no evidence of increased risk for cancer, autoimmune illness, and stroke.

Growth Factors and HIV-Infection in Children

1993 ◽  
Vol 21 (6) ◽  
pp. 342-345 ◽  
Author(s):  
G V Zuccotti ◽  
P Flumine ◽  
V Locatelli ◽  
G Banderali ◽  
E Riva
Keyword(s):  
Growth Factors ◽  
Leukocyte Count ◽  
Combined Therapy ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Chronic Anaemia ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Stimulating Factor

Three children with acquired immunodeficiency syndrome (AIDS) and chronic anaemia and leucopenia were treated with 5 μg/kg recombinant granulocyte colony-stimulating factor subcutaneously three times a week and 50 IU/kg erythropoietin subcutaneously twice a week. The therapy was not interrupted during the follow-up period. All children showed an increase of leukocyte count and haemoglobin levels. No transfusion was necessary and the number of admissions into hospital fell. These results suggest that combined therapy with granulocyte colony-stimulating factor and erythropoietin may improve leukopenia and anaemia, which is not zidovudine-related, in children who have AIDS.

scholarly journals Necrotising Fasciitis Caused by Adulterated Traditional Asian Medicine: A Case Report

2009 ◽  
Vol 17 (2) ◽  
pp. 223-226 ◽  
Author(s):  
Hitendra K Doshi ◽  
Joseph Thambiah ◽  
Cheng Leng Chan ◽  
Min En Nga ◽  
Paul Ananth Tambyah
Keyword(s):  
Case Report ◽  
Necrotising Fasciitis ◽  
Severe Neutropenia ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Asian Medicine ◽  
Life Threatening ◽  
Extensive Debridement ◽  
Stimulating Factor ◽  
Prompt Diagnosis

Necrotising fasciitis can be life threatening, requiring prompt diagnosis and surgical debridement. We report a case of necrotising fasciitis caused by an adulterate traditional Asian medication— Jamu Pegal Linu, containing toxic levels of phenylbutazone and dipyrone. The patient presented with severe neutropenia and sepsis. An urgent extensive debridement was carried out (within 6 hours of presentation). Repeated debridements were performed on days 2 and 5, augmented with antibiotics and granulocyte colony-stimulating factor.

Drug-induced agranulocytosis (clinical observation)

2021 ◽  
Vol 1 (30) ◽  
pp. 19-23
Author(s):  
N. A. Sokolova ◽  
L. V. Pozdnyakova ◽  
I. S. Tatarinova
Keyword(s):  
Adverse Effect ◽  
Clinical Observation ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Drug Induced ◽  
Life Threatening ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Antithyroid Agents ◽  
Stimulating Factor

The majority of agranulocytosis cases are caused by drugs, including nonsteroidal anti-inflammatory drugs, antibiotics, antithyroid agents, etc. Here, we report a case of severe agranulocytosis in a 67-year-old woman following nonsteroidal anti-inflammatory therapy which was successfully managed using recombinant human granulocyte colony-stimulating factor. Although metamizole, has been in use since 1922 in the management of postoperative pain, colic pain, cancer pain and migraine, agranulocytosis as a direct side effect of metamizole therapy has been rarely reported. It is important to keep in mind this rare but potentially life-threatening adverse effect of metamizole, when initiating therapy.

scholarly journals Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine

Blood ◽  
1991 ◽  
Vol 77 (10) ◽  
pp. 2109-2117 ◽  
Author(s):  
SA Miles ◽  
RT Mitsuyasu ◽  
J Moreno ◽  
G Baldwin ◽  
NK Alton ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Antimicrobial Agents ◽  
Opportunistic Infections ◽  
Combined Therapy ◽  
Hematologic Toxicity ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Transfusion Requirements ◽  
P24 Antigen ◽  
Stimulating Factor

Twenty-two patients with acquired immunodeficiency syndrome (AIDS) or severe AIDS-related complex and multilineage hematopoietic defects were treated with recombinant granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) in a phase I/II trial. All patients were neutropenic and anemic after withdrawal of all bone marrow-suppressive drugs. Daily, G-CSF was subcutaneously self-administered until an absolute neutrophil count (ANC) greater than 6,000/microL was achieved and maintained for 2 weeks. Subcutaneous EPO was added to the regimen and the dose increased until an increase of 15 g/L of hemoglobin was observed. Groups of patients were administered increasing doses of zidovudine to determine their tolerance. G-CSF and EPO therapy was continued with dose modification to maintain an ANC greater than 1,500/microL and hemoglobin greater than 100 g/L. The dose of zidovudine was not altered. All 22 patients responded to G-CSF with a mean 10-fold increase in neutrophils occurring in less than 2 weeks. Significant increases in CD4 and CD8 cell number, lymphocyte proliferative response, and bone marrow cellularity were seen. EPO therapy increased hemoglobin in all 20 evaluable patients within 8 weeks. Sixteen patients received 1,000 mg and four patients received 1,500 mg of zidovudine per day. The reinstitution of zidovudine resulted in a decline in reticulocytes and hemoglobin and the reappearance of transfusion requirements in eight of the 20 patients, six of whom had the study medications stopped. No patient had the study medications stopped because of neutropenia or thrombocytopenia. Toxicities were mild and did not require dose modifications. Limiting dilution plasma and lymphocyte co-cultures for HIV as well as serum p24 antigen levels did not change significantly during G-CSF or combined G- CSF and EPO therapy. HIV p24 antigen decreased significantly with zidovudine therapy. Opportunistic infections occurred in 14 patients but were successfully treated with myelosuppressive antimicrobial agents, including ganciclovir, without the development of neutropenia. These results suggest that combined therapy with G-CSF and EPO may improve the neutropenia and anemia of AIDS. Combined therapy may allow the resumption of full-dose zidovudine in most patients intolerant of the hematologic effects of zidovudine without apparent alteration of HIV expression or the efficacy of zidovudine.

scholarly journals Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine

Blood ◽  
1991 ◽  
Vol 77 (10) ◽  
pp. 2109-2117 ◽  
Author(s):  
SA Miles ◽  
RT Mitsuyasu ◽  
J Moreno ◽  
G Baldwin ◽  
NK Alton ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Antimicrobial Agents ◽  
Opportunistic Infections ◽  
Combined Therapy ◽  
Hematologic Toxicity ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Transfusion Requirements ◽  
P24 Antigen ◽  
Stimulating Factor

Abstract Twenty-two patients with acquired immunodeficiency syndrome (AIDS) or severe AIDS-related complex and multilineage hematopoietic defects were treated with recombinant granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) in a phase I/II trial. All patients were neutropenic and anemic after withdrawal of all bone marrow-suppressive drugs. Daily, G-CSF was subcutaneously self-administered until an absolute neutrophil count (ANC) greater than 6,000/microL was achieved and maintained for 2 weeks. Subcutaneous EPO was added to the regimen and the dose increased until an increase of 15 g/L of hemoglobin was observed. Groups of patients were administered increasing doses of zidovudine to determine their tolerance. G-CSF and EPO therapy was continued with dose modification to maintain an ANC greater than 1,500/microL and hemoglobin greater than 100 g/L. The dose of zidovudine was not altered. All 22 patients responded to G-CSF with a mean 10-fold increase in neutrophils occurring in less than 2 weeks. Significant increases in CD4 and CD8 cell number, lymphocyte proliferative response, and bone marrow cellularity were seen. EPO therapy increased hemoglobin in all 20 evaluable patients within 8 weeks. Sixteen patients received 1,000 mg and four patients received 1,500 mg of zidovudine per day. The reinstitution of zidovudine resulted in a decline in reticulocytes and hemoglobin and the reappearance of transfusion requirements in eight of the 20 patients, six of whom had the study medications stopped. No patient had the study medications stopped because of neutropenia or thrombocytopenia. Toxicities were mild and did not require dose modifications. Limiting dilution plasma and lymphocyte co-cultures for HIV as well as serum p24 antigen levels did not change significantly during G-CSF or combined G- CSF and EPO therapy. HIV p24 antigen decreased significantly with zidovudine therapy. Opportunistic infections occurred in 14 patients but were successfully treated with myelosuppressive antimicrobial agents, including ganciclovir, without the development of neutropenia. These results suggest that combined therapy with G-CSF and EPO may improve the neutropenia and anemia of AIDS. Combined therapy may allow the resumption of full-dose zidovudine in most patients intolerant of the hematologic effects of zidovudine without apparent alteration of HIV expression or the efficacy of zidovudine.

Granulocyte-Colony Stimulating Factor for Sulfasalazine-Induced Agranulocytosis

1993 ◽  
Vol 27 (9) ◽  
pp. 1052-1054 ◽  
Author(s):  
Barry J. Gales ◽  
Mark A. Gales
Keyword(s):  
Adverse Reactions ◽  
Antifungal Agents ◽  
Fungal Infections ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Colony Stimulating Factors ◽  
Empiric Antibiotics ◽  
Case Summary ◽  
Life Threatening ◽  
Stimulating Factor

OBJECTIVE: To report a case of sulfasalazine-induced agranulocytosis that was successfully treated with granulocyte-colony stimulating factor (G-CSF). CASE SUMMARY: An 82-year-old woman developed agranulocytosis within two months of initiating sulfasalazine therapy. She was hospitalized, empiric antibiotics and antifungal agents were prescribed, and sulfasalazine therapy was stopped. The patient received G-CSF 600 μg/d subcutaneously for six consecutive days, starting on hospital day 5. Agranulocytosis resolved on day 5 and leukopenia on day 6 of G-CSF therapy. No adverse reactions were attributed to administration of this agent and the patient was discharged on hospital day 13. DISCUSSION: Numerous agents, including sulfasalazine, have been associated with agranulocytosis. Agranulocytic patients frequently experience life-threatening bacterial and fungal infections. Administration of colony stimulating factors may reduce the duration of agranulocytosis and incidence of life-threatening infections. CONCLUSIONS: G-CSF administration appears to have decreased the duration of this elderly patient's agranulocytosis and hospitalization.

Sign in / Sign up

Export Citation Format

Share Document